Interestingly, CDKN2A‐inactivated pancreatic cancer exhibits increased sensitivity to paclitaxel and irinotecan, with paclitaxel in particular mimicking the effects of CDKN2A restoration [18]. Here, CDKN2A is linked to familial pancreatic carcinoma.